14 completed, 6 terminated, 3 recruiting, 2 unknown. 26 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 26 | Completed 14, Terminated 6, Recruiting 3, Unknown 2, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT Methotrexate, Anti-CD25 Monoclonal Antibody - Graft Versus Host Disease, Hematologic Neoplasms | Phase 3 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-05-01 | 2026-07-08 |
| Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation reduced-dose PTCy, Standard dose PTCY - Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease | Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 316 | 2025-01-01 | 2026-03-17 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day - Graft Versus Host Disease, Hematologic Malignancy | Phase 3 | Unknown | National Research Center for Hematology, Russia | 100 | 2022-01-01 | 2022-01-11 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease Brimonidine Tartrate, Placebos - Graft Versus Host Disease, Ocular Surface Disease | Phase 3 | Terminated | Ocugen | 59 | 2018-12-23 | 2022-07-06 |
| Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies Cyclophosphamide, ATG - Bone Marrow Transplant Complications, Graft Versus Host Disease | Phase 2 / Phase 3 | Recruiting | Hospital Israelita Albert Einstein | 50 | 2018-11-06 | 2019-02-01 |
| A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD GLASSIA, methylprednisolone or equivalent steroid, Albumin - Graft Versus Host Disease | Phase 2 / Phase 3 | Terminated | Baxalta now part of Shire | 1 | 2017-04-26 | 2021-01-13 |
| Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Tacrolimus and MMF. - Graft Versus Host Disease | Phase 3 | Unknown | Colorado Blood Cancer Institute | 50 | 2010-11-01 | 2014-07-01 |
| Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease prednisone, methylprednisolone, questionnaire administration - Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 164 | 2009-06-01 | 2017-08-21 |
| Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder cyclosporine ophthalmic emulsion, placebo - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 3 | Completed | Vanderbilt-Ingram Cancer Center | 164 | 2008-10-01 | 2017-03-07 |
| A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT ATG-F - Allogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease | Phase 3 | Terminated | Hadassah Medical Organization | 50 | 2008-05-01 | 2015-04-21 |
| Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD) Prochymal®, Placebo, Corticosteroid - Graft Versus Host Disease | Phase 3 | Completed | Mesoblast, Inc. | 192 | 2008-01-31 | 2022-01-19 |
| Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission thiotepa, cyclophosphamide, tacrolimus - B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission | Phase 3 | Completed | Children's Oncology Group | 146 | 2007-03-01 | 2019-08-07 |
| Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 3 | Completed | The Canadian Blood and Marrow Transplant Group | 230 | 2007-03-01 | 2014-03-05 |
| Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD) Prochymal®, Placebo, Standard of Care for GVHD - Graft Versus Host Disease | Phase 3 | Completed | Mesoblast, Inc. | 260 | 2006-08-17 | 2022-02-10 |
| Alefacept for Prevention of Graft Versus Host Disease (GVHD) Alefacept (AMEVIVE®), control group - Graft Versus Host Disease | Phase 3 | Terminated | Hadassah Medical Organization | 26 | 2006-06-01 | 2015-04-21 |
| Extracorporeal Photopheresis for Acute Graft Versus Host Disease Extracorporeal Photopheresis - Graft Versus Host Disease, Cancer | Phase 2 / Phase 3 | Completed | Ann & Robert H Lurie Children's Hospital of Chicago | 10 | 2003-07-01 | 2025-02-12 |
| Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation - Graft Versus Host Disease, Leukemia | Phase 3 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 72 | 2002-12-01 | 2014-04-17 |
| Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease cyclosporine, hydroxychloroquine, prednisone - Graft Versus Host Disease | Phase 3 | Completed | Children's Oncology Group | 82 | 2002-04-01 | 2014-02-14 |
| Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease beclomethasone dipropionate, methylprednisolone, prednisone - Graft Versus Host Disease | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 2002-04-01 | 2013-05-30 |
Showing 20 of 26. Sign in to see all of them.
Graft vs Host Disease (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Leukemia (7) · Lymphoma (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Myeloid, Accelerated Phase (6) · Leukemia, Myeloid, Chronic-Phase (6) · Lymphoma, Non-Hodgkin (6) · Burkitt Lymphoma (5) · Hodgkin Disease (5) · Leukemia, Myeloid, Acute (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Large-Cell, Immunoblastic (5)
Immune System Diseases (26) · Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Neoplasms (13) · Immunoproliferative Disorders (10) · Leukemia, Lymphoid (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms by Histologic Type (10) · Chronic Disease (8) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Leukemia, Myeloid (7) · Bone Marrow Diseases (6)
Methylprednisolone (7) · Cyclophosphamide (6) · Cyclosporine (5) · Methotrexate (5) · Prednisone (4) · Tacrolimus (4) · Radiotherapy (3) · Antilymphocyte Serum (2) · Filgrastim (2) · Peripheral Blood Stem Cell Transplantation (2) · remestemcel-l (2) · Adrenal Cortex Hormones (1) · Albumins (1) · Alefacept (1) · Beclomethasone (1)
Baxalta now part of Shire (2) · Children's Oncology Group (2) · Fred Hutchinson Cancer Center (2) · Hadassah Medical Organization (2) · Mesoblast, Inc. (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Chimeric Therapies (1) · Colorado Blood Cancer Institute (1) · Dana-Farber Cancer Institute (1) · Equillium (1) · Hospital Israelita Albert Einstein (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · National Research Center for Hematology, Russia (1)
United States (20) · Australia (7) · Canada (6) · Israel (3) · New Zealand (3) · China (2) · Italy (2) · Switzerland (2) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Portugal (1) · Puerto Rico (1) · Saudi Arabia (1)
Christopher James, PA (2) · Michael Y Shapira, MD (2) · Andrew L. Gilman, MD (1) · Andreza A Feitosa Ribeiro, PhD (1) · Elena Parovichnikova, MD, D.Sc (1) · Georgia B. Vogelsang, MD (1) · James N. Lowder, MD (1) · Jeffrey H. Lipton, MD, PhD (1) · Jiong HU (1) · John E. Wagner, MD (1) · Linghui Xia (1) · Madan Jagasia, MD (1) · Marco Mielcarek (1)
PMID 17889355, PMID 17925486, PMID 21149333, PMID 21669298, PMID 21689773, PMID 22157574, PMID 24497539, PMID 25862561, PMID 27515308, PMID 28935847
P01CA015396 (2), P30CA006973 (2), P01CA018029 (1), P30CA006516 (1), P30CA016056 (1), P30CA068485 (1), U10CA098543 (1)